These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11061732)

  • 1. Safety and costs of initiating angiotensin converting enzyme inhibitors for heart failure in primary care: analysis of individual patient data from studies of left ventricular dysfunction.
    Mason J; Young P; Freemantle N; Hobbs R
    BMJ; 2000 Nov; 321(7269):1113-6. PubMed ID: 11061732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ACE inhibitors in heart failure: what more do we need to know?
    Demers C; Mody A; Teo KK; McKelvie RS
    Am J Cardiovasc Drugs; 2005; 5(6):351-9. PubMed ID: 16259523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD).
    Knight EL; Glynn RJ; McIntyre KM; Mogun H; Avorn J
    Am Heart J; 1999 Nov; 138(5 Pt 1):849-55. PubMed ID: 10539815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of comorbidities on outcomes and angiotensin converting enzyme inhibitor effects in patients with predominantly left ventricular dysfunction and heart failure.
    Böhm M; Pogue J; Kindermann I; Pöss J; Koon T; Yusuf S
    Eur J Heart Fail; 2014 Mar; 16(3):325-33. PubMed ID: 24464788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction.
    Exner DV; Dries DL; Domanski MJ; Cohn JN
    N Engl J Med; 2001 May; 344(18):1351-7. PubMed ID: 11333991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute and long-term effects of the angiotensin-converting enzyme inhibitor, enalapril, on adrenergic activity and sensitivity during exercise in patients with left ventricular systolic dysfunction.
    Patten RD; Kronenberg MW; Benedict CR; Udelson JE; Kinan D; Stewart D; Yusuf S; Smith JJ; Kilcoyne L; Dolan N; Edens TR; Metherall J; Konstam MA
    Am Heart J; 1997 Jul; 134(1):37-43. PubMed ID: 9266781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.
    Granger CB; McMurray JJ; Yusuf S; Held P; Michelson EL; Olofsson B; Ostergren J; Pfeffer MA; Swedberg K;
    Lancet; 2003 Sep; 362(9386):772-6. PubMed ID: 13678870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction between aspirin and angiotensin-converting enzyme inhibitors: should they be used together in older adults with heart failure?
    Ahmed A
    J Am Geriatr Soc; 2002 Jul; 50(7):1293-6. PubMed ID: 12133028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cost effectiveness of ACE inhibition in therapy of chronic heart failure in Switzerland: evaluation based on the SOLVD study].
    Szucs TD; Goedde M; Berger K; Kiowski W
    Schweiz Med Wochenschr; 1997 Jul; 127(29-30):1234-41. PubMed ID: 9333933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators.
    Konstam MA; Kronenberg MW; Rousseau MF; Udelson JE; Melin J; Stewart D; Dolan N; Edens TR; Ahn S; Kinan D
    Circulation; 1993 Nov; 88(5 Pt 1):2277-83. PubMed ID: 8222122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators.
    Konstam MA; Rousseau MF; Kronenberg MW; Udelson JE; Melin J; Stewart D; Dolan N; Edens TR; Ahn S; Kinan D
    Circulation; 1992 Aug; 86(2):431-8. PubMed ID: 1638712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and risk factors of asymptomatic first-dose hypotension with angiotensin-converting enzyme inhibitors in chronic heart failure due to systolic dysfunction.
    Thanikachalam S; Manchanda SC
    Indian Heart J; 2003; 55(2):167-71. PubMed ID: 12921333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of chronic kidney disease and anemia on hospitalization expense in patients with left ventricular dysfunction.
    Gregory DD; Sarnak MJ; Konstam MA; Pereira B; Salem D
    Am J Cardiol; 2003 Dec; 92(11):1300-5. PubMed ID: 14636907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction.
    Dries DL; Exner DV; Gersh BJ; Domanski MJ; Waclawiw MA; Stevenson LW
    J Am Coll Cardiol; 1998 Sep; 32(3):695-703. PubMed ID: 9741514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials.
    Lakhdar R; Al-Mallah MH; Lanfear DE
    J Card Fail; 2008 Apr; 14(3):181-8. PubMed ID: 18381180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial.
    Al-Khadra AS; Salem DN; Rand WM; Udelson JE; Smith JJ; Konstam MA
    J Am Coll Cardiol; 1998 Feb; 31(2):419-25. PubMed ID: 9462588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction.
    Exner DV; Dries DL; Waclawiw MA; Shelton B; Domanski MJ
    J Am Coll Cardiol; 1999 Mar; 33(4):916-23. PubMed ID: 10091816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study.
    Jong P; Yusuf S; Rousseau MF; Ahn SA; Bangdiwala SI
    Lancet; 2003 May; 361(9372):1843-8. PubMed ID: 12788569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
    Young JB; Dunlap ME; Pfeffer MA; Probstfield JL; Cohen-Solal A; Dietz R; Granger CB; Hradec J; Kuch J; McKelvie RS; McMurray JJ; Michelson EL; Olofsson B; Ostergren J; Held P; Solomon SD; Yusuf S; Swedberg K;
    Circulation; 2004 Oct; 110(17):2618-26. PubMed ID: 15492298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptors Blockers on Mortality in Acute Heart Failure Patients with Left Ventricular Systolic Dysfunction in the Middle East: Observations from the Gulf Acute Heart Failure Registry (Gulf CARE).
    Al-Zakwani I; Sulaiman K; Al-Lawati JA; Alsheikh-Ali AA; Panduranga P; Al-Habib KF; Al Suwaidi J; Al-Mahmeed W; Al-Faleh H; Elasfar A; Al-Motarreb A; Ridha M; Bulbanat B; Al-Jarallah M; Bazargani N; Asaad N; Amin H
    Curr Vasc Pharmacol; 2018; 16(6):596-602. PubMed ID: 28820057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.